IMMUNOGENICITY IN MACAQUES OF A DNA/OLIGOMERIC ENVELOPE PROTEIN HIV VACCINE

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定是研究者机构。本研究旨在评价使用聚丙交酯-共乙交酯（PLG）微粒配制的临床级DNA和使用DNA/PLG引发蛋白加强方案的临床级HIV重组Env蛋白疫苗。本研究的第二个目的是比较M. mulatta和 M.束状的 在第0、4和8周用表达HIV-1 gag和env的质粒DNA接种猕猴。用阳离子PLG微粒配制质粒。在第24、36和48周，肌肉内给予与等体积MF-59佐剂混合的重组HIV gp 140 env蛋白的加强疫苗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study was designed to evaluate clinical-grade DNA formulated with polylactide-coglycolide (PLG) microparticles and clinical-grade, recombinant Env protein vaccines for HIV using a DNA/PLG prime protein boost regimen. A secondary goal of the study was to compare the immune responses of M. mulatta and M. fascicularis. Macaques were vaccinated at weeks 0, 4, and 8 with plasmid DNAs expressing HIV-1 gag and env. Plasmids were formulated with cationic PLG microparticles. Booster vaccinations with recombinant HIV gp140env protein mixed with an equal volume of MF-59 adjuvant were given intramuscularly at weeks 24, 36 and 48.